On Friday, Shares of Amplify Snack Brands Inc (NYSE:BETR), gained 3.12% to $16.19.
Amplify Snack Brands, declared the pricing of its initial public offering (IPO) of 15,000,000 shares of common stock to be sold by certain stockholders of Amplify at a public offering price of $18.00. The selling stockholders have also granted the underwriters a 30-day option to purchase up to 2,250,000 additional shares of common stock. The offering is predictable to close on August 10, 2015, subject to customary closing conditions.
All shares are being sold by existing stockholders, counting certain directors and officers of the Company. Amplify will not receive any of the proceeds from the offering.
Amplify Snack Brands, Inc. operates as a snack food company. It produces and delivers popcorn in various flavors, counting original, black pepper, white cheddar flavor, and naturally sweet, in addition to occasional rotational and Hatch Chile flavors under the SkinnyPop; and tortilla chips in original delights, cowboy ranch, roasted jalapeno, grilled habanero, very verde good, and haunted ghost pepper flavors under the Paqui brand.
Shares of Capnia Inc (NASDAQ:CAPN), declined -4.65% to $2.05, during its last trading session.
Capnia, declared financial results for the second quarter ended June 30, 2015.
“This is an exciting time for Capnia as we move forward with our neonatology, diagnostic and therapeutic platforms. In addition to our commercial-stage business, we have renewed our focus on our high-value therapeutics pipeline. The plans for ongoing to move the programs forward are rapidly taking shape,” said Anish Bhatnagar, M.D., Chief Executive Officer of Capnia. “The second quarter was marked by the commencement of our first clinical trial evaluating our proprietary nasal, non-inhaled carbon dioxide (nasal CO2) technology for the treatment of patients with cluster headache. We also successfully secured access to up to $10 million through a stock purchase agreement with Aspire Capital, which provides us with the resources necessary to fund the development of our pipeline. Looking ahead, we expect to initiate a clinical trial evaluating nasal CO2 for treatment of trigeminal neuralgia in Fall 2015, and determine a path forward for the allergic rhinitis indication.”
Capnia, Inc. develops diagnostics and therapeutics based on its proprietary technology for precision metering of gas flow primarily in the United States. The company offers CoSense for the diagnosis of excessive hemolysis in neonates, a condition that causes long-term developmental disability due to the degradation of red blood cells.
At the end of Friday’s trade, Shares of FLIR Systems, Inc. (NASDAQ:FLIR), gained 1.04% to $31.07.
FLIR Systems declared financial results for the second quarter ended June 30, 2015. Revenue was $393 million, up 6% contrast to second quarter 2014 revenue of $369.4 million. On a constant-currency basis, revenue for the second quarter was up 12% contrast to the preceding year, as foreign currency exchange fluctuations negatively influenced revenue by about $20 million. Operating income in the second quarter was $70.5 million, contrast to $59.4 million in the second quarter of 2014. Operating income was influenced by pretax charges related to formerly declared restructuring initiatives of $0.5 million in the second quarter of 2015 and $3.5 million in the second quarter of 2014. Second quarter 2015 net income was $50.5 million, or $0.36 per diluted share, contrast with net income of $44.8 million, or $0.31 per diluted share in the second quarter a year ago. Net income was influenced by after-tax restructuring charges of $0.3 million in the second quarter of 2015 and $2.7 million, or $0.02 per diluted share, in the second quarter of 2014. Cash offered by operations in the second quarter of 2015 was $48.9 million.
The Surveillance segment contributed $107.8 million of revenue during the second quarter, down 5% from the preceding year. The Instruments segment had $90.3 million of revenue, up 7% as compared to the preceding year, and was negatively influenced by foreign currency exchange fluctuations by about $7 million. FLIR’s OEM & Emerging Markets segment recorded revenue of $46.3 million in the second quarter, down 9% from the preceding year. Revenue from the Maritime segment was $52 million, down 6% from the second quarter of 2014, and was negatively influenced by foreign currency exchange fluctuations by about $7 million. Security segment revenue was $60 million, an enhance of 34% over the second quarter results last year. The Detection segment contributed $36.5 million of revenue, an enhance of 77% from the preceding year.
FLIR Systems, Inc. designs, manufactures, and markets thermal imaging, visible-light imaging systems, locater systems, measurement and diagnostic systems, and threat-detection solutions worldwide. The company operates in six segments: Surveillance, Instruments, OEM and Emerging Markets, Maritime, Security, and Detection.
Finally, Impax Laboratories Inc (NASDAQ:IPXL), ended its last trade with 1.66% gain, and closed at $47.07.
Impax Laboratories declared that the Company will release its second quarter 2015 financial results on Monday, August 10, 2015, preceding to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on August 10, 2015.
Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
